THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Connection

Chad Hamilton to Dose-Response Relationship, Drug

Back to Details
This is a "connection" page, showing publications Chad Hamilton has written about Dose-Response Relationship, Drug.
Chad Hamilton
Connection Strength
0.069
Dose-Response Relationship, Drug
  1. Final analysis of a phase I/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients. Cancer Med. 2019 08; 8(10):4678-4687.
    View in: PubMed
    Score: 0.037
  2. Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line. Hum Cell. 2017 Jul; 30(3):226-236.
    View in: PubMed
    Score: 0.031
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES